Related Experiment Video
Updated: Jan 19, 2026

10:20
Simultaneous Assessment of Kinship, Division Number, and Phenotype via Flow Cytometry for Hematopoietic Stem and Progenitor Cells
Published on: March 24, 2023
2.2K
Preliminary evaluation of a new flow cytometry method for the routine hematology workflow
Michela Seghezzi1, Valentina Moioli1, Giulia Previtali1
1Clinical Chemistry Laboratory, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Clinical Chemistry and Laboratory Medicine
|September 27, 2019
Summary
A new hybrid method integrating hematology analyzers and flow cytometry improves leukocyte differential counts. This cost-effective approach enhances first-level screening for pathological samples in clinical laboratories.
Area of Science:
- Clinical laboratory science
- Hematology
- Flow cytometry
Background:
- Integrating hematology analyzers (HAs) and multiparametric flow cytometry (FMC) can enhance first-level screening for pathological samples.
- A novel hybrid method (HM) was developed by incorporating HA reagents into FMC for leukocyte differential counting.
Purpose of the Study:
- To perform a preliminary evaluation of the new simple hybrid method (HM).
- To assess the utility of HM for routine clinical use and identification of morphological abnormalities.
Main Methods:
- Eighty-one peripheral blood samples were analyzed using standard methods and the HM.
- Analysis involved XN-module, CyFlow Space System, monoclonal antibodies, and optical microscopy (OM).
- Within-run imprecision, carryover, and data comparison (Passing-Bablok, Bland-Altman) were evaluated.
Main Results:
- HM within-run imprecision was comparable or lower than OM, ranging from 1.4% (neutrophils) to 10.1% (monocytes).
- Passing-Bablok regression showed slopes between 0.83 (lymphocytes) and 1.14 (monocytes).
- 100% agreement was observed between HM and OM for 11 pathological samples.
Conclusions:
- The hybrid method provides a leukocyte differential count suitable for routine clinical use.
- HM aids in identifying morphological abnormalities, reducing costs, and improving hematology workflow screening.

